Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Data ReadoutpositiveCapture-Seq™Positive

AI Analysis

Summary

VolitionRx reported publication of the first peer-reviewed paper on its Capture-Seq™ liquid biopsy technology targeting a $36 billion market in early cancer detection and MRD. The company is in active discussions with global diagnostic leaders to accelerate commercialization.

Outcome Details

First peer-reviewed paper published on Capture-Seq™ liquid biopsy technology

Importance:6/10

Sentiment:

0.70

liquid biopsyepigeneticscancer detectionMRDpeer-reviewed publicationcommercialization

Related Companies

$VNRX

Read the original article

Published by PR Newswire Biotech on August 5, 2026 12:17 PM

Read Original